Caxton Associates LP Allogene Therapeutics, Inc. Transaction History
Caxton Associates LP
- $3.12 Billion
- Q4 2024
A detailed history of Caxton Associates LP transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Caxton Associates LP holds 206,380 shares of ALLO stock, worth $334,335. This represents 0.01% of its overall portfolio holdings.
Number of Shares
206,380
Previous 242,102
14.75%
Holding current value
$334,335
Previous $677,000
35.16%
% of portfolio
0.01%
Previous 0.03%
Shares
10 transactions
Others Institutions Holding ALLO
# of Institutions
177Shares Held
139MCall Options Held
75.8KPut Options Held
52.8K-
Tpg Gp A, LLC Fort Worth, TX18.7MShares$30.3 Million1.1% of portfolio
-
Black Rock Inc. New York, NY16.4MShares$26.6 Million0.0% of portfolio
-
Lynx1 Capital Management LP San Juan, PR10.9MShares$17.6 Million9.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8MShares$13 Million0.0% of portfolio
-
State Street Corp Boston, MA7.25MShares$11.7 Million0.0% of portfolio
About Allogene Therapeutics, Inc.
- Ticker ALLO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 143,807,008
- Market Cap $233M
- Description
- Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...